With this transaction Grifols will control a 262 stake in Shanghai RAAS capital economic and voting rights in exchange for a non-majority share in Grifols Diagnostics Solutions 45 economic and 40 voting rights. Page 1 of 4 Grifols and Shanghai RAAS obtain authorization for their strategic alliance in China The operation is expected to close before the end of 2019 after the necessary approvals have been received from the regulatory authorities in the United States and the Peoples Republic of China Grifols will control a 262 stake in Shanghai RAAS economic and voting.
Grifols Shanghai Raas Acquisition A Share Swap Deal First Law Asia
Grifols SA agreed to acquire a 262 stake in Shanghai RAAS Blood Products Co Ltd making the Spanish company the second-largest shareholder in the Chinese maker of plasma-derived therapies.
. Grifols will obtain 262 of the economic and voting rights of Shanghai RAAS contributing 45 of the economic rights and 40 of the voting rights of its US subsidiary Grifols Diagnostic Solutions. Grifols controls a 2620 stake in Shanghai RAAS economic and voting rights in exchange for a non-majority share on behalf of Shanghai RAAS 45 economic rights and 40 voting rights in Grifols subsidiary Grifols Diagnostic Solutions GDS. Under the agreement the Catalan company will take a 262 percent stake in Shanghai RAAS in exchange for a stake of 45 percent with 40 percent voting rights in its US.
Grifols a top-three global manufacturers of plasma-derived medicines and Shanghai RAAS a leader in To continue reading The Pharma Letter please login subscribe or claim a 7 day free trial subscription and access exclusive features interviews round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space. Spains Grifols bought the stake in exchange for transferring a 45 economic rights and 40 voting rights in its US. Grifols and Shanghai RAAS close their strategic alliance in China Grifols controls a 2620 stake in Shanghai RAAS economic and voting rights in exchange for a non-majority share on behalf of Shanghai RAAS 45 economic rights and 40 voting rights in Grifols subsidiary Grifols Diagnostic Solutions GDS.
Subsidiary of Spanish blood products company Grifols the. As part of their strategic alliance Grifols will acquire a 262 stake in Shanghai RAAS capital to Grifols economic and voting rights in exchange for a non-majority share in Grifols Diagnostics Solutions 45 economic and 40 voting rights. Theme Healthcare Pharmaceuticals Grifols SA completed the acquisition of a 262 stake in Chinas Shanghai RAAS Blood Products Co.
Under the agreement Grifols will acquire its stake in Shanghai RAAS in exchange for 45 percent of the economic rights and 40 percent of the voting rights of Grifols Diagnostic Solutions its US subsidiary. Under the agreement the Catalan company will take a 262 percent stake in Shanghai RAAS in exchange for a stake of 45 percent with 40 percent voting rights in its US. Chinas Shanghai RAAS Blood Products Co Ltd is in talks to combine with a US.
Grifols Diagnostic Solutions valuation is 428 billion and the price per share of Shanghai RAAS is RMB 750. In exchange RAAS will take a 45 stake or 40 of voting rights in Grifols Diagnostics Solutions the companys US. Through the agreement Shanghai RAAS will also become the exclusive distributor of Grifols plasma products and transfusion diagnostics in China.
Grifols will maintain operating political and economic control of Grifols Diagnostics Solutions GDS. Specifically Grifols will control a 2620 stake in Shanghai RAASs capital economic and voting rights in exchange for a non-majority share in Grifols Diagnostics Solutions 45 economic and 40 voting rights on behalf of Shanghai RAAS. Subsidiary called Grifols Diagnostic Solutions.
Specifically Grifols will control a 2620 stake in Shanghai RAASs capital economic and voting rights in exchange for a non-majority share in Grifols Diagnostics Solutions 45 economic and 40 voting rights on behalf of Shanghai RAAS. Grifols controls a 2620 stake in Shanghai RAAS economic and voting rights in exchange for a non-majority share on behalf of Shanghai RAAS 45 economic rights and 40 voting rights in Grifols subsidiary Grifols Diagnostic Solutions GDS. Followed by Creat.
On the other hand Grifols would continue to have 60 of the voting rights of Grifols Diagnostic Solutions. Grifols will acquire 262 of economic and voting rights in Shanghai RASS in total valued at 38 billion euros contributing 45 of economic rights and 40 of voting rights of its US subsidiary Grifols Diagnostic Solutions in total valued at 5 billion euros. On March 7 2019 Grifols SA a Spanish pharmaceutical and chemical company that is a leading producer of blood plasma-based products entered into a purchase agreement to acquire Shanghai RAAS Blood Products Co Ltd which was subject to CFIUS clearance See Section 417 Agreement for Assets Purchase by Share Issue Grifos SA.
Grifols and Shanghai RAAS close their strategic alliance in China Grifols controls a 2620 stake in Shanghai RAAS economic and voting rights in exchange for a non-majority share on behalf of Shanghai RAAS 45 economic rights and 40 voting rights in Grifols subsidiary Grifols Diagnostic Solutions GDS. Grifols is Shanghai RAAS main shareholder with approximately a 2620 stake. In the transaction Grifols will give Shanghai RAAS 45 percent of the economic rights and 40 percent of the voting rights of its US.
For Grifols the agreement offers an opportunity to bolster its international expansion and build on its long-term sustainable growth. Barcelona-based Grifols upon clearance from regulatory authorities and completion of other closing conditions now has a 262 stake in Chinas Shanghai RAAS which has in return received 45 of the economic rights and 40 of the voting rights of US-based Grifols Diagnostic Solutions GDS which was earlier a fully owned subsidiary of Grifols. Business Grifols Diagnostic Solutions to the Chinese plasma-derived medicines maker.
Grifols will maintain operating political and economic control of Grifols Diagnostics Solutions GDS.
Grifols Shanghai Raas Acquisition A Share Swap Deal First Law Asia
Grifols Reports 13 Revenue Growth To Eur 1 157 Million And Confirms Its Solid Operational Performance
Grifols Sa 2022 Foreign Issuer Report 6 K
Grifols Shanghai Raas Acquisition A Share Swap Deal First Law Asia
Grifols Cierra Su Alianza Con Shanghai Raas Y Comienza A Cotizar En La Bolsa De Shenzhen Plantadoce
Grifols Se Convierte En El Mayor Accionista De La China Shanghai Raas
Grifols Ostentara Una Participacion Del 26 2 En La China Shanghai Raas Tras Cerrar Su Alianza Estrategica
Grifols Shanghai Raas Acquisition A Share Swap Deal First Law Asia
2
Grifols Parking Game The Related Party Control Financial Analysis Problem Valuesque
Grifols Se Lanza A Por Shanghai Raas Lider Chino En La Produccion De Medicamentos Plasmaticos Valencia Plaza
Grifols Maintains Its Operational Levels And Continues To Reinforce Its Commitment To Society
Grifols Parking Game The Related Party Control Financial Analysis Problem Valuesque
2
Grifols Adquirira El 26 2 De Shanghai Raas Para Expandirse En China Plantadoce
Grifols Shanghai Raas Acquisition A Share Swap Deal First Law Asia
Grifols Compra El 26 2 De La Empresa China Shanghai Raas
Grifols Y Shanghai Raas Cierran Su Alianza Estrategica En China Empresaexterior Noticias Del Comercio Exterior Y Negocio Internacional Espana
Grifols Reports 13 Revenue Growth To Eur 1 157 Million And Confirms Its Solid Operational Performance